重组人脑利钠肽对急性重症心力衰竭患者预后影响

Effect of Recombinant Human Brain Natriuretic Peptide on Prognosis of Patients with Acute Severe Heart Failure

目的:探讨重组人脑利钠肽(rh BNP)对急性重症心力衰竭患者预后的影响。方法:将2010年8月至2013年8月收治的急性重症心力衰竭患者237例随机分为观察组(n=120)和对照组(n=117),对照组给予异舒吉治疗,观察组给予rh BNP治疗,比较两组气促缓解时间、住院时间及治疗前后尿量、液体入量、左室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)、左心室舒张末期内径(LVDd)、N末端B型利钠肽原(NT-pro BNP)的变化。结果:治疗后,观察组24 h尿量、LVEF明显高于对照组(P<0.05);观察组呼吸困难缓解时间、住院时间、NT-pro BNP水平、不良心血管事件发生率均明显低于对照组(P<0.05)。结论 :rh BNP能有效改善急性重症心力衰竭患者左心室功能,缩短气促缓解时间、住院时间,降低不良心血管事件发生率。

Objective：To explore the effect of recombinant human brain natriuretic peptide （rhBNP）on the prognosis of patients with acute severe heart failure. Methods： 237 patients with acute severe heart failure were randomly divided into observation group （n=120） and control group （n=l17） treated by rhBNP and isosorbide dinitrate respectively from Aug 2010 to Aug 2013.The dyspnea remission time, hospitalization time and amount of urine before and after the treatment, the intake of liquid, left ventrieular ejection fraction （LVEF）, stroke volume （SV）, cardiac index （CI）, left ventricular end diastolic diameter （LVDd）, N terminal B type natriuretic peptide （NT-proBNP） changes were compared between the two groups. Results： Compared with the control group after the treatment, 24h urine volume and LVEF were significantly higher in the observation group （both P 〈 0.05）, and the dyspnea remission time, hospitalization time, NT-proBNP levels, adverse cardiovascular event rates were significantly lower in the observation group （all P 〈 0.05）. Conclusion：It can effectively improve left ventricular function, shorten the dyspnea remission time, hospitalization time, reduce the incidence of adverse cardiovascular events for patients with severe acute heart failure treated by rhBNP.